{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T07:51:32Z","timestamp":1648626692651},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1007\/s00108-004-1334-0","type":"journal-article","created":{"date-parts":[[2005,1,4]],"date-time":"2005-01-04T11:27:17Z","timestamp":1104838037000},"page":"75-82","source":"Crossref","is-referenced-by-count":2,"title":["Medikament\u00f6se Therapie der Harninkontinenz"],"prefix":"10.1007","volume":"46","author":[{"given":"M.","family":"Oelke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. J.","family":"de la Rosette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. C.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1464-410x.1998.00717.x","volume":"81","author":"Abrams","year":"1998","unstructured":"Abrams P, Freeman R, Anderstrom C, Mattiasson A (1998) Tolterodine, a new antimuscarinic agent: as effective butter better tolerated than oxybutynin in patients with overactive bladder. Br J Urol 81: 801?810","journal-title":"Br J Urol"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"Abrams","year":"2002","unstructured":"Abrams P, Cardozo L, Fall M et al. (2002) The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21: 167?178","journal-title":"Neurourol Urodyn"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0025-6196(11)62382-3","volume":"76","author":"Appell","year":"2001","unstructured":"Appell RA, Sand P, Dmochowski R et al. (2001) Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: Results of the OBJECT Study. Mayo Clin Proc 76: 358?363","journal-title":"Mayo Clin Proc"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/brain\/120.1.111","volume":"120","author":"Blok","year":"1997","unstructured":"Blok BFM, Willemsen ATM, Holstege G (1997) A PET study on brain control of micturition in humans. Brain 120: 111?121","journal-title":"Brain"},{"key":"CR5","first-page":"279","volume":"50","author":"Caulfiled","year":"1998","unstructured":"Caulfiled MP, Birdsall NJM (1998) International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 50: 279?290","journal-title":"Pharmacol Rev"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1464-410X.1990.tb14994.x","volume":"66","author":"Chapple","year":"1990","unstructured":"Chapple CR, Parkhouse H, Gardener C, Milroy EJG (1990) Double-blind, placebo-controlled, cross-over study of flavoxate in the treatment of idiopathic detrusor instability. Br J Urol 66: 491?494","journal-title":"Br J Urol"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1464-410X.2004.04561.x","volume":"93","author":"Chapple","year":"2004","unstructured":"Chapple CR, Arano P, Bosch JL, de Ridder D, Kramer AE, Ridder AM (2004) Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int 93: 71?77","journal-title":"BJU Int"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1464-410X.2004.04606.x","volume":"93","author":"Chapple","year":"2004","unstructured":"Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, Ridder A (2004) Rondomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93: 303?310","journal-title":"BJU Int"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000052265","volume":"34","author":"de Groat","year":"1998","unstructured":"de Groat WC (1998) Anatomy of the central neural pathways controlling the lower urinary tract. Eur Urol 34 [Suppl 1]: 2?5","journal-title":"Eur Urol"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4065\/78.6.687","volume":"78","author":"Diokno","year":"2003","unstructured":"Diokno AC, Appell RA, Sand PK et al. (2003) Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: Results of the OPERA trial. Mayo Clin Proc 78: 687?695","journal-title":"Mayo Clin Proc"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1097\/01.ju.0000080708.87092.cc","volume":"170","author":"Dmochowski","year":"2003","unstructured":"Dmochowski RR, Miklos JR, Norton PA, Zinner NR, Yalcin I, Bump RC (2003) Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol 170: 1259?1263","journal-title":"J Urol"},{"key":"CR12","first-page":"523","volume":"22","author":"Drutz","year":"2003","unstructured":"Drutz H, Cardozo L, Baygani S, Bump R (2003) Duloxetine treatment of women with only urodynamic stress incontinence awaiting continence surgery. Neurourol Urodyn 22: 523?524","journal-title":"Neurourol Urodyn"},{"key":"CR13","first-page":"426","volume":"245","author":"Durant","year":"1988","unstructured":"Durant PAC, Lucas PC, Yaksh TL (1988) Micturition in the unanesthetized rat: spinal vs. peripherial pharmacology of the adrenergic system. J Pharmacol Exp Ther 245: 426?435","journal-title":"J Pharmacol Exp Ther"},{"key":"CR14","first-page":"531","volume":"48","author":"Eglen","year":"1996","unstructured":"Eglen RM, Hedge SS, Watson N (1996) Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev 48: 531?565","journal-title":"Pharmacol Rev"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0014-2999(92)90788-6","volume":"221","author":"Espey","year":"1992","unstructured":"Espey MJ, Downie JW, Fine A (1992) Effect of 5-HT receptor and adrenoceptor antagonists on micturition in conscious cats. Eur J Pharmacol 221: 167?170","journal-title":"Eur J Pharmacol"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/sj.bjp.0704781","volume":"136","author":"Fetscher","year":"2002","unstructured":"Fetscher C, Fleichman M, Schmidt M, Krege S, Michel MC (2002) M3 muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol 136: 641?643","journal-title":"Br J Pharmacol"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.5414\/CPP40295","volume":"40","author":"Fr\u00f6hlich","year":"2002","unstructured":"Fr\u00f6hlich G, Bulitta M, Strosser W (2002) Trospium chloride in patients with detrusor overactivity. Meta-analysis of placebo-controlled, randomized, double-blind, multi-center clinical trials on the efficacy and safety of 20\u00a0mg trospium chloride twice daily. Int J Clin Pharmacol Ther 40: 295?303","journal-title":"Int J Clin Pharmacol Ther"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S0022-5347(05)65183-X","volume":"167","author":"Giannantoni","year":"2002","unstructured":"Giannantoni A, Di Stasi SM, Stephen RL, Navarra R, Scivoletto G, Mearini E, Porena M (2002) Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: A prospective randomized study. J Urol 167: 1710?1714","journal-title":"J Urol"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4088\/JCP.v63n0309","volume":"63","author":"Goldstein","year":"2002","unstructured":"Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA (2002) Duloxetin in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 63: 225?231","journal-title":"J Clin Psychiatry"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2004.01.008","volume":"45","author":"Haab","year":"2004","unstructured":"Haab F, Steward L, Dwyer P (2004) Darifenacin, an M-3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 45: 420?429","journal-title":"Eur Urol"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s00345-003-0321-8","volume":"20","author":"Halaska","year":"2003","unstructured":"Halaska M, Ralph G, Wiedemann A, Primus G, Ballering-Bruhl B, H\u00f6fner K, Jonas U (2003) Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 20: 392?399","journal-title":"World J Urol"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/S0895-4356(00)00232-8","volume":"53","author":"Hannestad","year":"2000","unstructured":"Hannestad YS, Rortveit G, Sandvik H, Hunskaar S (2000) A community-based epidemiological survey of female urinary incontinence: The Norwegian EPINCONT Study. J Clin Epidemiol 53: 1150?1157","journal-title":"J Clin Epidemiol"},{"key":"CR23","unstructured":"Hampel C, Wienhold D, Benken N, Eggersmann C, Th\u00fcroff JW (1997) Prevalence and natural history of female incontinence. Eur Urol 32, [Suppl] 2: 3?12"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/bmj.326.7394.841","volume":"326","author":"Herbison","year":"2003","unstructured":"Herbison P, Hay-Smith J, Ellis G, Moore K (2003) Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 326: 841?844","journal-title":"BMJ"},{"key":"CR25","unstructured":"H\u00f6fner K (2000) Pathophysiologie der Harninkontinenz. In: H\u00f6fner K, Jonas U (Hrsg) Praxisratgeber Harninkontinenz. UNI-MED, Bremen London Boston, S 43?63"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s003450100225","volume":"19","author":"H\u00f6fner","year":"2001","unstructured":"H\u00f6fner K, Oelke M, Machtens S, Gr\u00fcnewald V (2001) Trospium chloride?an effective drug in the treatment of overactive bladder and detrusor hyperreflexia. World J Urol 19: 336?343","journal-title":"World J Urol"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00120-003-0363-y","volume":"42","author":"H\u00f6fner","year":"2003","unstructured":"H\u00f6fner K (2003) Therapie der instabilen Blase?mit Antimuskarinika. Urologe A 42: 793?799","journal-title":"Urologe A"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1046\/j.1464-410X.2003.04468.x","volume":"92","author":"Homma","year":"2003","unstructured":"Homma Y, Paick JS, Lee JG, Kawabe K (2003) Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int 92: 741?747","journal-title":"BJU Int"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0090-4295(03)00755-6","volume":"62","author":"Hunskaar","year":"2003","unstructured":"Hunskaar S, Burgio K, Diokno A, Herzog AR, Hjalmas K, Lapitan MC (2003) Epidemiology and natural history of urinary incontinence in women. Urology 62 [Suppl 4A]: 16?23","journal-title":"Urology"},{"key":"CR30","first-page":"76","volume":"47","author":"Jonas","year":"1979","unstructured":"Jonas U, Wenderoth U (1979) Urodynamisch-r\u00f6ntgenologische Kombinationsuntersuchung: Erfahrungen mit 1000 Messungen bei Erwachsenen und Kindern. Elektromedica 47: 76?79","journal-title":"Elektromedica"},{"key":"CR31","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1055\/s-2003-42820","volume":"30","author":"Jost","year":"2003","unstructured":"Jost WH, Marsalek P (2003) Duloxetin: Wirkmechanismus am unteren Harntrakt und auf den Onuf-Nukleus. Akt Neurol 30: 397?400","journal-title":"Akt Neurol"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S0022-5347(17)35130-3","volume":"151","author":"Kasabian","year":"1994","unstructured":"Kasabian NG, Vlachiotis JD, Lais A, Klumpp B, Kelly MD, Siroky MB, Bauer SB (1994) The use of intravesical oxybutynin chloride in patients with detrusor hypertonicity and detrusor hyperreflexia. J Urol 151: 944?945","journal-title":"J Urol"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1442-2042.2002.00460.x","volume":"9","author":"Lee","year":"2002","unstructured":"Lee JG, Hong JY, Choo MS et al. (2002) Tolterodine: As effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder. Int J Urol 9: 247?252","journal-title":"Int J Urol"},{"key":"CR34","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1464-410X.2002.02905.x","volume":"90","author":"Leung","year":"2002","unstructured":"Leung HY, Yip SK, Cheon C et al. (2002) A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder. BJU Int 90: 375?380","journal-title":"BJU Int"},{"key":"CR35","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1464-410X.1995.tb07264.x","volume":"75","author":"Madersbacher","year":"1995","unstructured":"Madersbacher H, St\u00f6hrer M, Richter R, Burgdorfer H, Hachen HJ, M\u00fcrtz G (1995) Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. Br J Urol 75: 452?456","journal-title":"Br J Urol"},{"key":"CR36","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1046\/j.1464-410x.1999.00251.x","volume":"84","author":"Madersbacher","year":"1999","unstructured":"Madersbacher H, Halaska M, Voigt R, Alloussi S, H\u00f6fner K (1999) A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 84: 646?651","journal-title":"BJU Int"},{"key":"CR37","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/S0022-5347(05)66326-4","volume":"165","author":"Malone-Lee","year":"2001","unstructured":"Malone-Lee J, Shaffu B, Anand C, Powell C (2001) Tolterodine: Superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: A randomized controlled study. J Urol 165: 1452?1456","journal-title":"J Urol"},{"key":"CR38","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00120-003-0365-9","volume":"42","author":"Michel","year":"2003","unstructured":"Michel MC (2003) Neue pharmakologische Therapiekonzepte bei instabiler Blase. Urologe A 42: 807?811","journal-title":"Urologe A"},{"key":"CR39","doi-asserted-by":"crossref","unstructured":"Michel MC, Oelke M, Peters SL (2005) The neuro-urological connection. Eur Urol [Suppl 4]: 18?28","DOI":"10.1016\/j.eursup.2004.10.004"},{"key":"CR40","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1464-410X.2004.04607.x","volume":"93","author":"Millard","year":"2004","unstructured":"Millard RJ, Moore K, Rencken R, Yalcin I, Bump RC (2004) Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. BJU Int 93: 311?318","journal-title":"BJU Int"},{"key":"CR41","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1067\/mob.2002.124840","volume":"187","author":"Norton","year":"2002","unstructured":"Norton PA, Zinner NR, Yalcin I, Bump RC (2002) Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 187: 40?48","journal-title":"Am J Obstet Gynecol"},{"key":"CR42","unstructured":"Oelke M (2000) Diagnostik der Harninkontinenz. In: H\u00f6fner K, Jonas U (Hrsg) Praxisratgeber Harninkontinenz. UNI-MED, Bremen London Boston, S 65?81"},{"key":"CR43","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.eururo.2003.12.004","volume":"45","author":"Reitz","year":"2004","unstructured":"Reitz A, St\u00f6hrer M, Kramer G et al. (2004) European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45: 510?515","journal-title":"Eur Urol"},{"key":"CR44","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1159\/000280289","volume":"34","author":"Rud","year":"1979","unstructured":"Rud T, Andersson KE, Ulmstein U (1979) Effects of nifedipine in women with unstable bladders. Urol Int 34: 421?429","journal-title":"Urol Int"},{"key":"CR45","first-page":"243","volume":"15","author":"Sand","year":"2004","unstructured":"Sand PK, Miklos J, Ritter H, Appell R (2004) A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women. Int J Urogyn 15: 243?248","journal-title":"Int J Urogyn"},{"key":"CR46","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1185\/030079902125000570","volume":"18","author":"Sussman","year":"2002","unstructured":"Sussman D, Garely A (2002) Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: The antimuscarinic clinical effectiveness trial (ACET). Curr Med Res Opin 18: 177?184","journal-title":"Curr Med Res Opin"},{"key":"CR47","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/ageing\/26.5.367","volume":"26","author":"Thom","year":"1997","unstructured":"Thom DH, Haan MN, VandenEeden SK (1997) Medically recognized urinary incontinence and risk factors of hospitalization, nursing home admission and mortality. Age Ageing 26: 367?374","journal-title":"Age Ageing"},{"key":"CR48","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1532-5415.1998.tb02469.x","volume":"46","author":"Thom","year":"1998","unstructured":"Thom D (1998) Variation in estimates of urinary incontinence prevalence in the community: effects of differences in definition, population characteristics, and study type. J Am Geriatr Soc 46: 473?480","journal-title":"J Am Geriatr Soc"},{"key":"CR49","first-page":"1014","volume":"274","author":"Thor","year":"1995","unstructured":"Thor KB, Katofiasc MA (1995) Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther 274: 1014?1024","journal-title":"J Pharmacol Exp Ther"},{"key":"CR50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0090-4295(03)00754-4","volume":"62","author":"Thor","year":"2003","unstructured":"Thor KB (2003) Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: Implications for treating stress urinary incontinence. Urology 62 [Suppl 1]: 3?9","journal-title":"Urology"},{"key":"CR51","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-4295(00)01113-4","volume":"57","author":"van Kerrebroeck","year":"2001","unstructured":"van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein AN (2001) Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 57: 414?421","journal-title":"Urology"},{"key":"CR52","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1471-0528.2004.00067.x","volume":"111","author":"van Kerrebroeck","year":"2004","unstructured":"van Kerrebroeck P, Abrams P, Lange R, Slack M, Wyndaele JJ, Yalcin I, Bump RC (2004) Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. Br J Obstet Gynaecol 111: 249?257","journal-title":"Br J Obstet Gynaecol"},{"key":"CR53","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0090-4295(97)00623-7","volume":"51","author":"Wagner","year":"1998","unstructured":"Wagner TH, Hu TW (1998) Economic costs of urinary incontinence in 1995. Urology 51: 355?360","journal-title":"Urology"},{"key":"CR54","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0090-4295(02)01784-3","volume":"60","author":"Wein","year":"2002","unstructured":"Wein AJ, Rovner ES (2002) Definition and epidemiology of overactive bladder. Urology 60 [Suppl 1]: 7?12","journal-title":"Urology"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-004-1334-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-004-1334-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-004-1334-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T06:09:43Z","timestamp":1586066983000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-004-1334-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["1334"],"URL":"https:\/\/doi.org\/10.1007\/s00108-004-1334-0","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}